• LAST PRICE
    1.0300
  • TODAY'S CHANGE (%)
    Trending Up0.0100 (0.9804%)
  • Bid / Lots
    1.0100/ 8
  • Ask / Lots
    1.0600/ 1
  • Open / Previous Close
    1.0300 / 1.0200
  • Day Range
    Low 1.0000
    High 1.1200
  • 52 Week Range
    Low 0.6550
    High 5.5600
  • Volume
    400,091
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Yesterday

      Show headlines and story abstract
    • 11 hours ago by MT Newswires
      Companies Mentioned: PIII
      04:12 PM EDT, 03/28/2024 (MT Newswires) -- ...
    • 11 hours ago by Dow Jones
      Companies Mentioned: PIII
    • 11 hours ago by Business Wire
      Companies Mentioned: PIII

      --Affirming 2024 guidance

      --Anticipates reaching Adjusted EBITDA positive in 2024

      --Management to Host Conference Call and Webcast March 28, 2024 at 4:30 PM ET

      P3 Health Partners Inc. ("P3" or the "Company") (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced its financial results for the fourth quarter and full year ended December 31, 2023, and affirmed its 2024 guidance.

    • 11 hours ago by Dow Jones
      Companies Mentioned: PIII
      Pahrump operations, (v) expenses for third-party consultants to assist us with the development, implementation, and documentation of new and enhanced internal controls and processes for compliance with Sarbanes-Oxley Section 404(b), (vi) a legal settlement outside of the ordinary course of business, and (vii) valuation allowance on our notes receivable. Other during the year ended December 31, 2022 consisted of (i) income related to the release of indemnity funds previously escrowed as part of an acquisition in a prior year and (ii) interest income, offset by (iii) accounting, legal, and professional services expenses incurred related to the restatement of our consolidated financial statements for the years ended December 31, 2020, 2019, and 2018 and the condensed consolidated financial statements for the quarterly periods ended March 31, 2021, June 30, 2021, September 30, 2021, March 31, 2020, June 30, 2020, and September 30, 2020, (iv) expenses for third-party consultants to assist us with the development, implementation, and documentation of new and enhanced internal controls and processes for compliance with Sarbanes-Oxley Section 404(b), and (v) severance expense. MEDICAL MARGIN (in thousands, except PMPM) (unaudited) Three Months Ended December 31, Year Ended December 31, ------------------------- --------------------------- 2023 2022 2023 2022 ------------- ---------- ------------ ------------- Capitated revenue $ 342,836 $ 254,025 $ 1,252,309 $1,034,800 Less: medical claims expenses (333,761) (247,458) (1,117,258) (972,725) -------- -------- ---------- --------- Medical margin $ 9,075 $ 6,567 $ 135,051 $ 62,075 ======== ======== ========== ========= Medical margin PMPM $ 28 $ 22 $ 108 $ 52 RECONCILIATION OF GROSS PROFIT TO MEDICAL MARGIN (in thousands) (unaudited) Three Months Ended December 31, Year Ended December 31, ----------------------- ------------------------- 2023 2022 2023 2022 ------------ --------- ------------ ----------- Gross profit(1) $(20,818) $(10,965) $ 31,635 $ (7,753) Other patient service revenue (4,025) (4,188) (14,066) (14,671) Other medical expense 33,918 21,720 117,482 84,499 ------- ------- ------- ------- Medical margin $ 9,075 $ 6,567 $135,051 $ 62,075 ======= ======= ======= ======= _____________________ (1) Effective for the quarter ended June 30, 2023, we modified the method by which we reconcile medical margin. Previously, we reconciled medical margin to operating loss as the most directly comparable measure calculated in accordance with GAAP. In the current period and on a go-forward basis we will reconcile to gross profit as we have determined that gross profit is the most directly comparable GAAP measure.
  • Mar 15, 2024

      Show headlines and story abstract
    • 8:05AM ET on Friday Mar 15, 2024 by Dow Jones
      Companies Mentioned: PIII

      services; our ability to fund our growth and expand our operations; changes in laws and regulations applicable to our business; our ability to maintain our relationships with health plans and other key payers; the impact of COVID-19, including the impact of new variants of the virus, or another pandemic, epidemic or outbreak of infectious disease on our business and results of operation; increased labor costs; our ability to recruit and retain qualified team members and independent physicians; and other factors discussed in Part I, Item 1A. "Risk Factors" of the Company's Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 31, 2023, as updated by Part II, Item 1A. "Risk Factors" in the Company's Quarterly Report on Form 10-Q for the period ended September 30, 2023 and in the Company's other filings with the SEC. All information in this press release is as of the date hereof, and we undertake no duty to update or revise this information unless required by law. You are cautioned not to place undue reliance on any forward-looking statements contained in this press release.

Peers Headlines